In the majority of melanomas, the RAS/RAF/MEK/ERK signalling pathway is constitutively activated either due to oncogenic mutations in B-RAF and N-RAS genes or through autocrine growth factor stimulation [1]. This evidence concerns the gene BRAF and melanoma.